Dr. Lees is a clinical stroke researcher with a background in clinical pharmacology and cardiovascular medicine. His stroke service possesses independent carotid and vertebral Doppler, transcranial Doppler and CT scanning equipment and radiography/sonography staff. He has extensive experience with protocol design and all stages of clinical development of neuroprotective compounds and thrombolytics. He co-authored the influential STAIR statement on preclinical assessment of putative stroke treatments. He chaired the steering committee for the SAINT and CHANT programme with NXY-059. Prof Lees was also Principal Investigator for GAIN International and IMAGES trials.
He is the UK coordinator and steering committee member for the SITS-MOST trial that proved safety of alteplase in routine clinical use. He has chaired independent data monitoring committees for the ASTIN and ICTUS neuroprotection trials, and for the DIAS, DEDAS and ECASS-III Trials with desmoteplase and alteplase. Dr. Lees is the Clinical Outcomes Chairman for the CLEAR III trial and serves on its executive committee.
Design of clinical trials depends on relationships between entry criteria, baseline prognostic factors and outcome measures. Prof Lees founded the Virtual International Stroke Trials Archive (VISTA). This resource of >20,000 patients’ data maximizes value from patient participation in research.
Assessment of clinical outcome is crucial in trials. Prof Lees developed a DVD-based training and certification tool for the modified Rankin Scale, already in eight languages. His team is developing methods to strengthen outcome assessment further and has been responsible for advances in endpoint analysis approaches.
Dr. Wendy Ziai is Assistant Professor of Neurology, Neurosurgery, and Anesthesia/Critical Care Medicine at Johns Hopkins, Dr. Ziai is a member of the Neurological Critical Care team. She manages critically ill patients with neurologic and neurosurgical diseases. Particular interests include subarachnoid hemorrhage, intracerebral and intraventricular hemorrhage, hypothermia and intensive care unit (ICU) resource allocation.
Dr. Ziai’s research interests include platelet dysfunction in intracerebral hemorrhage, intraventricular rt-PA for intraventricular hemorrhage, and markers of vasospasm in subarachnoid hemorrhage. Dr. Ziai serves on multiple international committees for the CLEAR III international Trial and is the CLEAR III site principal investigator for the Johns Hopkins University.
Dr. Ziai currently sees patients at The Johns Hopkins Hospital and Bayview Medical Center neurointensive Care Units.